Cost-effectiveness of second-line ipilimumab for metastatic melanoma: A real-world population-based cohort study of resource utilization.
Cancer Med
; 12(10): 11451-11461, 2023 05.
Article
de En
| MEDLINE
| ID: mdl-36999965
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Qualité de vie
/
Mélanome
Type d'étude:
Clinical_trials
/
Etiology_studies
/
Health_economic_evaluation
/
Health_technology_assessment
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Aspects:
Patient_preference
Limites:
Humans
Pays/Région comme sujet:
America do norte
Langue:
En
Journal:
Cancer Med
Année:
2023
Type de document:
Article
Pays d'affiliation:
Canada